Portal de investigación
Satisfacción de pacientes y médicos con el tratamiento actual para la hemoglobinuria paroxística nocturna en España. Estudio SATURNO.
Datos básicos
- Código:
- NP-20459
- Protocolo:
- NP-20459
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2022
- Año de finalización:
- 2023
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis.
Puerta-Alcalde, Pedro; (...); Garcia-Vidal, Carolina
Article. 10.1093/mmy/myac038. 2022
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; (...); Bonanad, Santiago
Article. 10.1016/j.jgo.2022.10.016. 2022
Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-166826. 2022
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
Martinez, Carmen; (...); Garcia-Sanz, Ramon
Article. 10.1007/s00277-022-05011-6. 2022
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
Mosquera Orgueira, Adrian; (...); Hernandez Boluda, Juan Carlos
Meeting Abstract. 10.1182/blood-2022-158669. 2022
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
Mosquera-Orgueira A; (...); Hernández-Boluda JC
Article. 10.1097/HS9.0000000000000818. 2023
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Kim, Won-Seog; (...); Walewski, Jan
Meeting Abstract. 10.1182/blood-2022-158406. 2022
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Luna, A.; (...); Garcia-Gutierrez, V
Article. 10.1007/s00277-022-04932-6. 2022
Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
Lakhwani, Sunil; (...); Hernandez, Miguel-Teodoro
Meeting Abstract. 10.1182/blood-2022-167247. 2022
Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
Mosquera Orgueira, Adrian; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-159429. 2022
Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors
Aguila, Sonia; (...); Ferrer Marin, Francisca
Meeting Abstract. 10.1182/blood-2022-163070. 2022
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Perez-Lamas, Lucia; (...); Garcia-Gutierrez, Valentin
Article. 10.3390/cancers15041045. 2023
Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
Perez-Lamas, Lucia; (...); Garcia Gutierrez, Valentin
Meeting Abstract. 10.1182/blood-2022-167453. 2022
TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
Montoro Gomez, Maria Julia; (...); Valcarcel, David
Meeting Abstract. 10.1182/blood-2022-165257. 2022